Ceftobiprole-A novel cephalosporin to combat MRSA

Eastern Journal of Medicine

Volumn 16, Issue 1, 2011, Pages 1-8

  Rizvi, Mehnaz Waris ^a   Shujatullah, Fatima ^a   Malik, Abida ^a   Khan, Haris M ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Ceftobiprole; Cephalosporin; Cocci; MRSA

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; ORAL CONTRACEPTIVE AGENT; PENICILLIN BINDING PROTEIN; PROBENECID; PRODRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PNEUMONIA; PRURITUS; RASH; SKIN INFECTION; SOFT TISSUE INFECTION; TASTE DISORDER; VOMITING;

EID: 79956190204     PISSN: 13010883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Kontou P, Kuti JL, Nicolau DP. Ceftobiprole. The first anti-MRSA cephalosporin antibiotic. Formulary 2008; 32: 66-78.
2. Kisgen J, Whitney D. Ceftobiprole, a Broad- Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). PT 2008; 33: 631-641.
3. Mehta AA, Rodrigues CC, Kumar RR, et al. A pilot programme of MRSA surveillance in India. (MRSA Surveillance Study Group). J Postgrad Med 1996; 42: 1-3.
4. Tyagi A, Kapil A, Singh P. Incidence of methicillin resistant Staphylococcus aureus (MRSA) in pus samples in a tertiary care hospital, AIIMS, New Delhi. J Indian Acad Clin Med 2008; 9: 33-35.
5. Vidhani S, Mehndiratta PL, Mathur MD. Study of methicillin resistant Staphylococcus aureus (MRSA) isolates from high risk patients. Indian J Med Microbiol 2001; 19: 87-90.
6. Verma S, Joshi S, Chitnis V, Hemwani N, Chitnis D. Growing problem of methicillin resistant staphylococci - Indian scenario. Indian J Med Sci 2000; 54: 535-540.
7. Choudhary U, Anupama. Prevalence of methicillin resistance in Staphylococcus aureus. Indian J Med Microbiol 1999; 17: 154-155.
8. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-674.
9. Hsueh PR, Teng LJ, Chen WH, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother 2004; 48: 1361- 1364.
10. Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC. Resistance to teicoplanin developing during treatment of methicillinresistant Staphylococcus aureus infection. J Antimicrob Chemother 2002; 49: 423-424.
11. Hiramatsu K, Hanaki H, Ino T, et al. Methicillinresistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
12. Utsui Y, Yokota T. Role of an altered penicillinbinding protein in methicillin- and cephemresistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 397-403.
13. Adis R&D profile Ceftobiprole medocaril. Drugs RD 2006; 7: 305-311. Available at adisonline.com
14. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6: 156.
15. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistant staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008; 57: 72-79.
16. Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int J Antimicrob Agents 2003; 21: 521-524.
17. James ME. In vitro profile of a new β-lactam, ceftibiprole, with activity against methicillinresistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13: 17-24.
18. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-932.
19. Bustos C, Pozo JLD. Emerging agents to combat complicated and resistant infections: focus on ceftobiprole. Infection Drug Resist 2010; 3: 5-14.
20. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-4219.
21. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52: 864-868.
22. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 884-888.
23. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti- MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008; 47: 21-33.
24. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 2570-2575.
25. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of anovel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 2576-2580.
26. Schmitt-Hoffman AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1030.
27. Roos B, Schmidt-Hoffman A, Schleimer M. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function. Presented at the 43rd Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract A-23.
28. Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007; 51: 2378-2387.
29. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13: 25-29.
30. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44.
31. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-655.
32. Nicholson SC, Strauss RS, Michiels B, Noel GJ. Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with communityacquired pneumonia. Presented at the American Thoracic Society International Conference; May 16-21, 2008; Toronto. Poster C-17.
33. Basilea announces positive top-line data from phase III study of ceftobiprole in hospital-acquired pneumonia. Basel: Basilea Pharmaceutica Ltd.; October 9, 2007. Available at www.basilea.com
34. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including betalactamase- producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 2007; 51: 2043-2047.
35. Issa NC, Rouse MS, Piper KE, et al. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004; 48: 73-75.
36. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008; 61: 595-602.
37. Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2006; 50: 2050-2057.
38. Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-836.
39. Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007; 58: 133-136.
40. Borg MA, de Kraker M, Scicluna E, et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 2007; 60: 1310-1315.
41. Fadeyi A, Bolaji BO, Oyedepo OO, et al. Methicillin-resistant Staphylococcus aureus carriage among health care workers of the critical care units in a Nigerian hospital. Am J Infect Dis 2010; 6: 18-23.
42. Kresken M, Brauers J, Korber-Irrgang B, Menke A, Romfeld C. In vitro activity of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa by time-kill methodology. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007; Chicago, IL, USA. Poster E- 273. www. Antiinfectives-intelligence.de/de / wirueberuns 6.2.html
43. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2974-2976.
44. Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother 2009; 53: 3294- 3301.
45. Cottagnoud M, Acosta F, Stuki F, Gerber P, Cottagnoud PH. Ceftobiprole is superior to cefepime against a Klebsiella pneumoniae strain in experimental meningitis. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases; April 2008; Barcelona, Spain. Abstract P1933. www. blackwellpublishing. com/eccmid18/abstract.asp?id=69831.
46. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998; 317: 657-660.